美国商业保险女性宫颈癌筛查方式趋势(2013-2019)
结果显示单纯细胞学检查使用率下降,30-64岁女性联合筛查上升,HPV单独检测始终低于0.5%,且18-20岁女性每年有8.7%-13.6%接受筛查,提示年轻女性存在不适当筛查。
要点
- 21-29岁女性单纯细胞学检查使用率从2013年34.2%降至2019年26.4%(P<.0001)。
- 30-64岁女性单纯细胞学检查从18.9%降至8.6%,联合筛查从14.9%升至19.3%(均P<.0001)。
- 所有年龄组HPV单独检测年使用率始终低于0.5%,18-20岁女性每年8.7%-13.6%接受筛查。
核心结论
- 商业保险女性宫颈癌筛查方式的变化与临床指南更新趋势一致。
- 21岁以下女性中存在较多不适当的宫颈癌筛查。
研究设计与样本
- 基于IBM MarketScan商业及Medicare补充数据库的回顾性趋势分析。
- 采用双侧Poisson回归评估2013-2019年筛查方式使用趋势。
主要发现
- 21-29岁女性单纯细胞学检查使用率从2013年34.2%降至2019年26.4%(P<.0001)。
- 30-64岁女性单纯细胞学检查从18.9%降至8.6%(P<.0001),联合筛查从14.9%升至19.3%(P<.0001)。
- 所有年龄组HPV单独检测年使用率在整个研究期间均低于0.5%。
- 18-20岁女性每年有8.7%-13.6%接受宫颈癌筛查。
- 不同都市居住地和人口普查区域的筛查方式使用存在持续差异,但时间趋势相似。
临床怎么用
- 临床医生应遵循指南,避免对21岁以下女性进行宫颈癌筛查。
- 在30-64岁女性中可考虑采用联合筛查或HPV单独检测,但需注意HPV单独检测实际使用率极低。
- 需关注不同地区和居住地之间的筛查方式差异,促进指南一致性实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine trends in the use of cervical cancer screening tests during 2013-2019 among commercially insured women. METHODS: The study population included women of all ages with continuous enrollment each year in the IBM MarketScan commercial or Medicare supplemental databases and without known history of cervical cancer or precancer (range = 6.9-9.8 million women per year). Annual cervical cancer screening test use was examined by three modalities: cytology alone, cytology plus HPV testing (cotesting), and HPV testing alone. Trends were assessed using 2-sided Poisson regression. RESULTS: Use of cytology alone decreased from 34.2% in 2013 to 26.4% in 2019 among women aged 21-29 years (P < .0001). Among women aged 30-64 years, use of cytology alone decreased from 18.9% in 2013 to 8.6% in 2019 (P < .0001), whereas cotesting use increased from 14.9% in 2013 to 19.3% in 2019 (P < .0001). Annual test use for HPV testing alone was below 0.5% in all age groups throughout the study period. Annually, 8.7%-13.6% of women aged 18-20 years received cervical cancer screening. There were persistent differences in screening test use by metropolitan residence and census regions despite similar temporal trends. CONCLUSIONS: Temporal changes in the use of cervical cancer screening tests among commercially insured women track changes in clinical guidelines. Screening test use among individuals younger than 21 years shows that many young women are inappropriately screened for cervical cancer.
引用
- Qin J, Shahangian S, Saraiya M, et al. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019. Gynecol Oncol. 2021. PMID: 34507826. doi:10.1016/j.ygyno.2021.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。